Last updated: February 24, 2026
CRT therapy still relies on three core criteria that clinicians should confirm together before implantation.
| Criterion | Threshold | Evidence Level |
|---|---|---|
| NYHA Functional Class | II-IV despite optimal medical therapy | Class I |
| Left Ventricular Ejection Fraction | ≤35% | Class I |
| QRS Duration with LBBB | ≥150ms | Class I |
| Sinus Rhythm | Preferred (or controlled AFib) | Class IIa |
Patients should receive guideline-directed medical therapy including ACE inhibitors or ARBs, beta-blockers, and mineralocorticoid receptor antagonists at maximally tolerated doses. CRT using biventricular pacing is indicated over right ventricular pacing in patients with LVEF ≤50% and high pacing burden, or LVEF ≤30% and QRS duration ≥130ms, with landmark trials showing reduced mortality and fewer heart failure events.
CRT candidacy starts with confirmed heart failure with reduced ejection fraction that persists despite at least three months of optimized medical therapy.
Primary Qualification Checklist:
Patients who meet these criteria typically gain better functional capacity, fewer hospitalizations, and potential survival benefit.
Current CRT guidance now extends beyond traditional biventricular pacing and places stronger emphasis on conduction system pacing.
The 2025 EHRA/ESC consensus recommends LBBAP as the preferred conduction system pacing modality in routine practice for distal conduction delay or CRT indications. This shift supports more physiologic activation of the ventricles.
Key 2026 Guideline Evolutions:
Conduction system pacing CRT functions as a physiologic alternative to biventricular CRT, especially for non-responders, with evidence of improved QRS duration, better clinical outcomes, and lower risk of new-onset atrial fibrillation.
The decision between CRT-P and CRT-D depends on sudden cardiac death risk, comorbidities, and patient preferences.
| Feature | CRT-P | CRT-D | Best For |
|---|---|---|---|
| Battery Life | 8-12+ years | 5-8 years | Low SCD risk patients |
| SCD Protection | Limited | Full defibrillation | High arrhythmia risk |
| Mortality Benefit | HF improvement | 19-36% reduction vs CRT-P | Ischemic cardiomyopathy |
| Device Size | Smaller/lighter | Larger | Patient preference |
A network meta-analysis of 13 randomized controlled trials with more than 12,000 patients found CRT-D reduced total mortality by 19% compared with CRT-P. However, patients older than 75 years showed no significant mortality difference between CRT-D and CRT-P, which supports tailored device selection.
Certain subgroups still benefit from CRT when clinicians apply modified criteria.
Special Consideration Scenarios:
Clinicians should review absolute and relative contraindications carefully before CRT implantation.
Major Contraindications:
Post-implant CRT monitoring often fragments across multiple OEM portals, which creates data silos and inconsistent workflows.
Clinicians then face alert fatigue, overlooked critical events, and missed reimbursement opportunities from incomplete CPT code capture.
Rhythm360 resolves these issues through vendor-neutral integration that reaches >99.9% data transmissibility using redundant feeds, computer vision, and AI-driven extrapolation. The platform cuts critical alert response times by 80% and increases practice revenue by about 300% through automated CPT 93298/93299 billing documentation.
Critical Monitoring Parameters:
Consider a Saturday morning scenario where Rhythm360’s AI flags new-onset atrial fibrillation in a CRT patient. By Saturday afternoon, the care team initiates anticoagulation, which may prevent a stroke that a fragmented monitoring setup could miss. Schedule a Rhythm360 demo to see unified CRT monitoring across all device manufacturers.
Remote monitoring after discharge reduced primary endpoints at 90 days with a hazard ratio of 0.54, showing meaningful improvement in heart failure outcomes. AI-based predictive analytics further support earlier intervention before patients clinically deteriorate.
Rhythm360’s mobile application gives HIPAA-compliant access to key patient data so clinicians can review transmissions, sign reports, and coordinate care from any location. This access maintains continuity of care and lowers administrative workload through automated EHR integration with Epic, Cerner, and other major systems.
The platform’s communication hub records every patient interaction with full audit trails, which removes redundant follow-up calls and supports complete documentation for billing compliance.
Core indications include NYHA Class II-IV heart failure symptoms despite optimal medical therapy, left ventricular ejection fraction ≤35%, and QRS duration ≥150ms with left bundle branch block morphology. Patients should be in sinus rhythm or have well-controlled atrial fibrillation and show adherence to guideline-directed medical therapy including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists.
CRT-P suits patients with low sudden cardiac death risk who value longer battery life and smaller device size. CRT-D fits patients at high risk for ventricular arrhythmias, particularly those with ischemic cardiomyopathy, because it provides about 19-36% mortality reduction compared with CRT-P. The final choice should follow shared decision-making that considers age, comorbidities, and patient goals.
The 2026 guidelines highlight conduction system pacing, especially left bundle branch area pacing, as a primary alternative to traditional biventricular CRT. Updates also include multipoint pacing strategies for non-responders and a stronger focus on individualized patient selection algorithms. Core criteria remain NYHA II-IV, LVEF ≤35%, and QRS ≥150ms with LBBB.
Remote patient monitoring platforms such as Rhythm360 bring data from all device manufacturers into a single view and cut alert response times by about 80% through AI-based triage. These tools support early detection of arrhythmias, device issues, and heart failure decompensation, which enables proactive interventions that reduce hospitalizations and improve outcomes.
Key CPT codes include 93298 for interrogation device evaluation and 93299 for remote monitoring. Rhythm360 automates documentation and billing workflows, which helps practices capture previously missed revenue and reach up to 300% growth in monitoring-related income through detailed audit trails and EHR integration.
Clear understanding of CRT indications under the 2026 guidelines, combined with robust remote patient monitoring, forms a strong foundation for better outcomes and healthier margins. The move toward conduction system pacing and AI-supported monitoring now defines the next phase of cardiac resynchronization therapy. Schedule a demo today to see how Rhythm360 supports CRT patient management with vendor-neutral monitoring and automated revenue capture.
